DeepMed Research

Nimotuzumab

Generic Name: Nimotuzumab

Drug Type: Biotech

CAS Number: 780758-10-3

Unique Ingredient Identifier: 6NS400BXKH

Indication: Investigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.

Associated Conditions: Advanced Head and Neck Cancer, Advanced Stage Head and Neck Cancer, Glioblastoma Multiforme (GBM), High Grade Glioma (HGG), Advanced Epithelial Tumor of the Head and Neck

Clinical Trials

Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma

Phase 3

Completed

Conditions: Palliative Treatment
Monoclonal Antibody in Cervical Cancer Treatment
Cervical Cancer Recurrent or Persistent

Interventions: Drug: mAb Nimotuzumab
Device: Placebo

First Posted Date: 2014-03-11

Last Posted Date: 2015-04-14

Lead Sponsor: National Institute of Cancerología

Target Recruit Count: 168

Registration Number: NCT02083211

Locations: 🇲🇽
National Institute of Cancerología, México, Tlalpan, Mexico

Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus

Phase 2

Withdrawn

Conditions: Squamous Cell Carcinoma of Esophagus

Interventions: Drug: Nimotuzumab

First Posted Date: 2014-01-22

Last Posted Date: 2015-03-05

Lead Sponsor: Zhejiang University

Registration Number: NCT02041819

Locations: 🇨🇳
The first affiliated hospital, Zhejiang University, Zhejiang, Zhejiang, China

Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma

Phase 2

Withdrawn

Conditions: Stage IV Esophageal Squamous Cell Carcinoma

Interventions: Drug: Nimotuzumab

First Posted Date: 2014-01-14

Last Posted Date: 2015-03-05

Lead Sponsor: Zhejiang University

Registration Number: NCT02034968

Locations: 🇨🇳
The first affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China

Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC

Phase 3

Completed

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: TPF neoadjuvant chemotherapy
Drug: Concurrent nimotuzumab during radiotherapy
Drug: Concurrent chemotherapy with cisplatin during radiotherapy
Radiation: Radical radiotherapy

First Posted Date: 2013-12-16

Last Posted Date: 2019-04-10

Lead Sponsor: Fudan University

Target Recruit Count: 160

Registration Number: NCT02012062

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma

Phase 2

Withdrawn

Conditions: Stage IV Esophageal Squamous Cell Carcinoma

Interventions: Drug: Placebo
Drug: Nimotuzumab

First Posted Date: 2013-12-13

Last Posted Date: 2015-02-12

Lead Sponsor: Zhejiang University

Registration Number: NCT02011594

Locations: 🇨🇳
Qiong Zhao, Hangzhou, Zhejiang, China
🇨🇳
The first affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China

Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.

Phase 1

Conditions: Esophageal Squamous Cell Cancer

Interventions: Drug: nimotuzumab

First Posted Date: 2013-11-25

Last Posted Date: 2013-11-25

Lead Sponsor: Peking University

Target Recruit Count: 9

Registration Number: NCT01993784

Locations: 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China

Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Nimotuzumab
Drug: docetaxel
Drug: capecitabine

First Posted Date: 2013-09-11

Last Posted Date: 2015-06-04

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 90

Registration Number: NCT01939054

Locations: 🇨🇳
Xijing Hospital, Xi-an, Shanxi, China
🇨🇳
The General Hospital of the People's Liberation Army (PLAGH), Beijing, Beijing, China
🇨🇳
Beijing cancer hospital, Beijing, Beijing, China

and more 6 locations

Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer

Phase 2

Conditions: Locally Advanced Rectal Cancer

Interventions: Radiation: Preoperative irradiation
Drug: Nimotuzumab
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2013-07-15

Last Posted Date: 2013-07-15

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 50

Registration Number: NCT01899118

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer

Phase 3

Terminated

Conditions: Gastroesophageal Junction Cancer
Gastric Cancer

Interventions: Drug: Irinotecan
Drug: Nimotuzumab

First Posted Date: 2013-03-18

Last Posted Date: 2018-03-26

Lead Sponsor: Kuhnil Pharmaceutical Co., Ltd.

Target Recruit Count: 400

Registration Number: NCT01813253

Locations: 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇰🇷
Hwansun Junnam hospital, Gwangju, Korea, Republic of

Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma

Phase 2

Conditions: Esophageal Squamous Cell Carcinoma Resectable

Interventions: Drug: Nimotuzumab combined with paclitaxel and cisplatin

First Posted Date: 2012-09-20

Last Posted Date: 2012-09-20

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 60

Registration Number: NCT01688700

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy